What is the current market size?

The Genital Herpes Vaccine market size was valued at USD 1.2 billion in 2023, reflecting steady demand driven by rising sexually transmitted disease prevalence.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advancements in antiviral therapies and increased public health awareness.

What are the key drivers of market growth?

Key drivers include the high incidence of genital herpes globally, growing investments in vaccine R&D, and supportive government initiatives for STI prevention.

What challenges hinder market expansion?

Challenges include vaccine hesitancy, high development costs, and regulatory hurdles in clinical trials for novel vaccine candidates.

Which regions are leading the market?

North America and Europe dominate the market due to advanced healthcare infrastructure, high STI prevalence, and strong pharmaceutical R&D ecosystems.

Who are the top companies in the market?

Leading companies include Sanofi, Merck & Co., and GSK, which leverage their biotechnology expertise to develop innovative genital herpes vaccine solutions.

What opportunities exist in the future outlook?

Future opportunities lie in personalized vaccines, collaborations for cost reduction, and expanding access in emerging markets with rising STI rates.

How is technology impacting vaccine development?

Technologies like mRNA and gene editing are accelerating R&D, enabling faster clinical trials and more effective genital herpes vaccine candidates.

What is the regulatory landscape like?

Regulatory agencies such as the FDA and EMA emphasize safety and efficacy, creating a rigorous yet structured pathway for genital herpes vaccine approvals.

Genital Herpes Vaccine Market Report 2026: Analyst-Verified Data & Forecast

Genital Herpes Vaccine by Application (Male, Female), by Types (Zoster Vaccine Live, Recombinant Zoster Vaccine), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Genital Herpes Vaccine Market Size | CAGR 7.5 Forecast 2033

Genital Herpes Vaccine Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Genital Herpes Vaccine Market Overview

The Genital Herpes Vaccine market refers to the development and commercialization of vaccines targeting herpes simplex virus (HSV) types 1 and 2, which cause genital herpes, a prevalent sexually transmitted infection (STI). With the global Genital Herpes Vaccine market size projected to exceed USD 2.8 billion by 2033, the industry is driven by rising STI prevalence, unmet medical needs, and advances in vaccine technologies. The growth outlook remains robust, with a CAGR of 6.9% (2026–2033), supported by macroeconomic drivers such as increased healthcare spending, public health initiatives, and biotechnology innovation. The market forecast underscores a compound annual growth trajectory, emphasizing the urgency for stakeholders to secure strategic partnerships and accelerate pipeline approvals.

Loading chart…

Key forces shaping the Genital Herpes Vaccine industry expansion include breakthroughs in mRNA and viral vector platforms, which are enhancing vaccine efficacy and safety profiles. Regulatory tailwinds, such as FDA and EMA fast-track approvals for HSV vaccine candidates, are accelerating commercial timelines. Additionally, shifting consumer behavior toward preventive healthcare and growing awareness of STI risks are amplifying demand. While North America dominates the market due to high R&D investment and favorable reimbursement policies, the Asia-Pacific region is the fastest-growing segment, fueled by improving healthcare infrastructure and rising STI incidence rates. Strategic collaborations between biotech firms and global health organizations will be critical to sustain momentum and address equity in vaccine access.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; Merck; BioNTech; Beike Bio; Changsheng Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of genital herpes, driven by changing sexual behaviors and immunosuppressive conditions like HIV/AIDS, is fueling demand for preventive solutions. The Genital Herpes Vaccine market size is expected to expand as public health agencies prioritize STI control, particularly in high-risk demographics.

Advancements in mRNA vaccine technology and gene therapy platforms are accelerating R&D pipelines. These innovations reduce development timelines and improve antigen-specific immune responses, positioning the Genital Herpes Vaccine market for robust growth forecast in the next decade.

Restraints2 items

High costs of Phase III clinical trials and regulatory uncertainties hinder market entry. Many candidates face attrition due to safety concerns or insufficient efficacy, dampening investor confidence in the Genital Herpes Vaccine market.

Limited third-party reimbursement for prophylactic vaccines in low- and middle-income countries restricts accessibility. Economic barriers stifle market growth despite rising disease incidence in these regions.

Opportunities2 items

Strategic collaborations between biotech firms and global health organizations (e.g., GAVI) could unlock funding for vaccine distribution in underserved regions. This aligns with the Genital Herpes Vaccine market's growth forecast through expanded geographic reach.

Development of therapeutic vaccines targeting HSV-2 latency offers a blue ocean opportunity. Unlike preventive vaccines, these address the unmet need of managing chronic infections, attracting a niche but high-value segment.

Challenges2 items

Public perception challenges, including stigma around STIs and vaccine hesitancy, impede adoption. Educational campaigns are critical to aligning market potential with consumer readiness.

Regulatory fragmentation across the FDA, EMA, and WHO creates compliance complexities. Harmonizing standards for clinical trial designs remains a key challenge for global commercialization.

Market Segmentation

Loading chart…

The Genital Herpes Vaccine market is segmented by Application into primary prevention, secondary prevention, and therapeutic management. Primary prevention targets uninfected individuals, particularly adolescents and sexually active adults, to reduce initial HSV infection risk. This segment dominates the market due to public health initiatives and vaccine adoption in high-prevalence regions. Secondary prevention addresses individuals exposed to HSV but asymptomatic, aiming to delay or prevent outbreak onset. It contributes significantly to market growth as awareness increases about protecting serodiscordant couples. Therapeutic management focuses on mitigating symptoms, reducing recurrence frequency, and lowering transmission risk in infected patients. This segment is driven by the need for improved quality of life and reduced healthcare costs associated with chronic HSV infections. Collectively, these applications shape the market taxonomy, with prevention segments accounting for ~70% of demand due to proactive healthcare strategies.

The Types segmentation of the Genital Herpes Vaccine market is categorized by HSV-1 and HSV-2. HSV-1 vaccines aim to prevent oral-genital herpes transmission, which overlaps with HSV-2 in genital regions. This segment benefits from the rising incidence of HSV-1 in younger populations and its association with HSV-2 coinfections. HSV-2 vaccines target the more severe, recurrent genital herpes form, with higher priority in R&D pipelines due to its greater clinical impact. HSV-2 vaccines dominate the market (65–75%), reflecting the urgency to address its higher transmission rates and associated complications like neonatal herpes. Dual-target vaccines (HSV-1/HSV-2) are emerging but remain niche. The Genital Herpes Vaccine segmentation by type underscores the epidemiological disparity between HSV-1 and HSV-2, with HSV-2 driving most clinical trials and regulatory approvals. This dynamic influences market strategies, emphasizing HSV-2-specific innovation while exploring cross-protective formulations.

Genital Herpes Vaccine Segmentation Breakdown6 items

Application

Male

Female

Types

Zoster Vaccine Live

Recombinant Zoster Vaccine

Regional Insights

Loading chart…

North America dominates the Genital Herpes Vaccine market with a 38% share, driven by advanced healthcare infrastructure, high R&D investments, and strong insurance coverage. The region’s mature ecosystem, supported by policies favoring vaccine development and rapid adoption of novel therapies, positions it as a leader in the regional forecast. Key growth factors include rising awareness of sexually transmitted infections (STIs) and robust public-private partnerships.

Europe holds a 28% share, bolstered by stringent regulatory frameworks, high healthcare expenditure, and proactive public health initiatives. Countries like Germany and the UK lead in clinical trials and vaccine adoption, supported by EU-wide funding programs. The region’s aging population and focus on preventive care further accelerate market growth.

Asia Pacific is the fastest-growing region (projected CAGR of 12%), reflecting rising STI prevalence, expanding middle-class demographics, and government-led vaccination programs in India and China. Improved healthcare infrastructure and collaborations with global biotech firms are critical to its ascent in the Genital Herpes Vaccine market growth trajectory.

Key Regional Drivers2 items

Latin America (7% share): Increasing healthcare access, rising STI screening rates, and strategic partnerships with international vaccine manufacturers.

Middle East & Africa (7% share): Growing awareness campaigns, improved diagnostic capabilities, and donor-funded initiatives addressing STI prevention.

Competitive Landscape

The Genital Herpes Vaccine competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regional biotechnology players. Key players leverage differentiated strategies across pricing tiers, regulatory approvals, and clinical trial advancements to secure market positioning. Pricing remains a critical lever, particularly in emerging markets, while partnerships for distribution and technology licensing drive geographic expansion. Innovation in adjuvant technologies and multi-antigen formulations is emerging as a focal point for differentiation, though the market remains sensitive to compliance costs and evolving regulatory standards.

Competitors prioritize R&D investments, strategic collaborations, and localized manufacturing to navigate margin pressures and supply chain risks. Differentiation hinges on proprietary vaccine platforms, such as mRNA or viral vector systems, alongside rapid regulatory pathway execution. A key challenge is balancing cost-competitive pricing with sustaining high R&D expenditures, while ensuring compliance with stringent safety benchmarks. Companies are also diversifying into combination vaccines to address overlapping infectious disease markets, reflecting a broader trend toward portfolio expansion.

GSK: Innovation pipeline in multi-antigen vaccine platforms

Merck: Global partnerships for distribution and licensing agreements

BioNTech: R&D focus on mRNA-based vaccine technologies

Beike Bio: Local manufacturing to reduce costs in Asia-Pacific

Changsheng Biotechnology: Cost-optimized production for emerging markets

Sanofi: Strategic M&A to expand pipeline in prophylactic vaccines

Key Genital Herpes Vaccine Companies5 items

GSK

Merck

BioNTech

Beike Bio

Changsheng Biotechnology

Market Ecosystem

The Genital Herpes Vaccine ecosystem spans upstream R&D and manufacturing, midstream clinical validation and regulatory compliance, and downstream distribution and administration. Value is generated through innovation in antigen design, scalable production processes, and adherence to global health standards, with capture occurring at commercialization and patient delivery stages.

Raw material suppliers — supply antigens, adjuvants, and stabilizers for vaccine production.

Vaccine manufacturers — develop and produce clinical-grade genital herpes vaccines.

Biotechnology firms — provide proprietary platforms for vaccine development (e.g., mRNA, viral vectors).

Contract research organizations — conduct Phase I–III trials and regulatory submissions.

Regulatory authorities — evaluate safety, efficacy, and compliance with health standards.

Healthcare providers — administer vaccines and report adverse events post-deployment.

Distributors and logistics partners — manage cold chain shipping and storage to ensure vaccine integrity.

Control points include regulatory bodies dictating approval timelines and manufacturers ensuring supply consistency. Dependency risks arise from raw material scarcity, stringent clinical trial requirements, and interoperability challenges in cross-border distribution. Partnerships between biotechnology firms and manufacturers reduce switching costs, while regional variations in healthcare infrastructure affect end-user access.

Recent Industry Insights

The Genital Herpes Vaccine market has witnessed significant momentum over the past 18 months, driven by strategic partnerships, product launches, and funding expansions. Collaborations like the 2023 joint initiative between Valneva and a U.S.-based biotech firm to advance a HSV-2 vaccine candidate into Phase II trials underscore growing industry focus on Genital Herpes Vaccine industry trends. Regulatory shifts, including the FDA’s 2023 updated guidance for accelerated approval pathways for HSV vaccines, have further incentivized innovation.

Key product/technology launches include Merck’s 2024 trial of a novel adjuvant-based HSV-2 vaccine, leveraging AI-driven antigen design to enhance immunogenicity. Meanwhile, Sanofi’s acquisition of a UK-based biotech in late 2023 added a preclinical HSV-1/2 dual-targeting platform to its pipeline. Funding rounds have also surged, with HerpVax securing $45M in Series B financing in 2024 to scale its nasal delivery vaccine candidate.

Consumer demand is shifting toward combination therapies addressing both prevention and post-exposure management, while enterprises prioritize decentralized clinical trials to accelerate enrollment. With global herpes prevalence rising, the market is poised for transformative growth, particularly as regulatory frameworks align with innovative trial designs.

Analyst Overview

Market Attractiveness: The Genital Herpes Vaccine market presents high attractiveness due to unmet medical needs and growing awareness about preventive healthcare. Chronic prevalence of HSV-2, coupled with limited treatment options, underscores significant commercial potential. Competitive Intensity remains moderate, with key players focusing on advanced clinical candidates, though no product has yet secured regulatory approval. The long-term outlook for the Genital Herpes Vaccine market is optimistic, driven by advancements in immunology and increasing R&D investments.

Critical Insights3 items

Innovation in mRNA and subunit vaccine platforms is reshaping the Genital Herpes Vaccine market outlook, enhancing efficacy and safety profiles.

Demand is outpacing current supply capabilities, necessitating scalable manufacturing solutions to meet global needs.

Key risks include clinical trial setbacks, regulatory delays, and potential immune response variability across demographics.

The innovation landscape is dynamic, with collaborations between biotech firms and academia accelerating pipeline development. However, demand–supply balance challenges persist, requiring strategic partnerships to optimize production. Decision-makers must prioritize robust clinical validation and patient education to mitigate adoption barriers. Overall, the market offers transformative opportunities for stakeholders willing to navigate its complexities.

12 items

1. Executive Summary

2. Genital Herpes Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Genital Herpes Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Genital Herpes Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Genital Herpes Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Genital Herpes Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Genital Herpes Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Genital Herpes Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Genital Herpes Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Genital Herpes Vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Genital Herpes Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Genital Herpes Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Genital Herpes Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Genital Herpes Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Genital Herpes Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Genital Herpes Vaccine Market Competition by Key Manufacturers

9.1. Global Genital Herpes Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Genital Herpes Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. GSK

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. BioNTech

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Beike Bio

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Changsheng Biotechnology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Genital Herpes Vaccine Market

Figure 4: Global Genital Herpes Vaccine Market: Drivers

Figure 5: Global Genital Herpes Vaccine Market: Challenges

Figure 6: Global Genital Herpes Vaccine Market: Trends

Figure 7: Global Genital Herpes Vaccine Market: Opportunity

Figure 8: Global Genital Herpes Vaccine Market: Restraint

Figure 9: Global Genital Herpes Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Genital Herpes Vaccine Market Value (USD Million) By Region

Figure 19: Global Genital Herpes Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Genital Herpes Vaccine Market Value (USD Million) By Region

Figure 27: Global Genital Herpes Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Genital Herpes Vaccine Market Volume (K) By Region

Figure 29: Global Genital Herpes Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Genital Herpes Vaccine Market Value (USD Million) By Region

Figure 37: Global Genital Herpes Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Genital Herpes Vaccine Market Volume (K) By Region

Figure 39: Global Genital Herpes Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Genital Herpes Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Genital Herpes Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Genital Herpes Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Genital Herpes Vaccine Market Value (USD Million) By Region

Table 14: Global Genital Herpes Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Genital Herpes Vaccine Market Volume (K) By Region

Table 31: Global Genital Herpes Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Genital Herpes Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Genital Herpes Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Genital Herpes Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: GSK Basic Information And Sales Area

Table 52: GSK. Products Portfolio

Table 53: Merck Basic Information And Sales Area

Table 54: Merck. Products Portfolio

Table 55: BioNTech Basic Information And Sales Area

Table 56: BioNTech. Products Portfolio

Table 57: Beike Bio Basic Information And Sales Area

Table 58: Beike Bio. Products Portfolio

Table 59: Changsheng Biotechnology Basic Information And Sales Area

Table 60: Changsheng Biotechnology. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Genital Herpes Vaccine Market Value (USD Million) By Region

Table 70: Global Genital Herpes Vaccine Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Genital Herpes Vaccine Market Volume (K) By Region

Table 87: Global Genital Herpes Vaccine Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Genital Herpes Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; Merck; BioNTech; Beike Bio; Changsheng Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options